Large‐Scale Plasma Proteomics Identifies Early Molecular Deviations and Improves Risk Prediction for Heart Failure Among Individuals With Obesity
Diabetes, Obesity and Metabolism, 2026
Li M., He X., Hu B., Gu F., Li X., Shu C., Zhu Z., Li J.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Metabolic Diseases CVD | Patient Stratification | Plasma |  Olink Explore 3072/384 |
Abstract
Aims
Heart failure (HF) is a major global public health challenge, with obesity being one of its key risk factors. Although several HF risk prediction models have been developed in the general population, few are specifically tailored to individuals with obesity. This underscores the urgent need for precise biomarkers to improve individual risk stratification and enable personalized prevention strategies. We aimed to develop and validate a plasma proteomics‐based protein risk score (PRS) to predict incident HF among individuals with obesity.
Materials and Methods
We analysed 9831 participants with obesity (BMI ≥ 30 kg/m 2 ) from the UK Biobank with baseline measurements of 2911 circulating proteins and up to 16 years of follow‐up. Multivariable Cox regression identified proteins associated with incident HF after comprehensive covariate adjustment. A PRS was constructed using LASSO regression and evaluated in a held‐out test set. Protein trajectories before HF onset were reconstructed using LOESS modelling. To enhance clinical feasibility, a minimal protein panel was identified using LightGBM with forward feature selection.
Results
A total of 727 participants developed HF during follow‐up. Multivariable cox analyses identified 578 proteins significantly associated with HF. LASSO regression further selected 81 proteins to build the PRS, which showed a strong association with HF risk in both training (HR 3.57; 95% CI 3.19–4.00) and test cohorts (HR 2.45; 95% CI 2.20–2.74). Adding the PRS improved prediction beyond age and sex (Δ C = 0.091) and beyond the Pooled Cohort Equations to Prevent Heart Failure (PCP‐HF) model (Δ C = 0.052), with consistent gains in NRI and IDI. Proteomic deviations were detectable up to 16 years before diagnosis. A four‐protein panel (GDF15, NT‐proBNP, TNFRSF10B, CTHRC1) achieved robust discrimination (AUC 0.789), outperforming NT‐proBNP alone (AUC 0.695) and complementing the PCP‐HF model (combined AUC 0.803).
Discussion
Large‐scale plasma proteomics substantially improves HF risk prediction in individuals with obesity and reveals long‐standing molecular alterations preceding clinical onset. A simplified four‐protein panel maintains robust predictive accuracy and provides a practical approach for the early detection and targeted prevention of obesity‐related HF.